Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2004)Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391-400

[3] Xu J(2003)Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60-65

[4] Ward E(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342

[5] Ferrara N(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019

[6] Hillan KJ(2010)Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 845-852

[7] Gerber HP(2007)Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539-1544

[8] Novotny W(2006)Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer BioDrugs 20 193-195

[9] Kabbinavar F(2009)Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 1842-1847

[10] Hurwitz HI(2006)Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway J Clin Oncol 24 2035-740

[1] Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300

[2] Siegel R(2004)Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391-400

[3] Xu J(2003)Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60-65

[4] Ward E(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342

[5] Ferrara N(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019

[6] Hillan KJ(2010)Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 845-852

[7] Gerber HP(2007)Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539-1544

[8] Novotny W(2006)Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer BioDrugs 20 193-195

[9] Kabbinavar F(2009)Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 1842-1847

[10] Hurwitz HI(2006)Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway J Clin Oncol 24 2035-740